Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | CCR3 | P51677 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 5/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6274732 | 0.92 | CCR3 (0.34) | BCHECCR3DRD2CCR1 | |
| SCHEMBL8306421 | 0.84 | DRD4 (0.36) | CCR3CCR1OPRM1OPRL1 | |
| SCHEMBL6098492 | 0.84 | DRD4 (0.36) | CCR3CCR1OPRM1OPRL1 | |
| SCHEMBL6098489 | 0.84 | DRD4 (0.36) | CCR3CCR1OPRM1OPRL1 | |
| SCHEMBL6095673 | 0.82 | CCR1 (0.39) | CCR1 | |
| SCHEMBL8312296 | 0.82 | CYP2D6 (0.37) | CCR1 | |
| SCHEMBL6095667 | 0.82 | CCR1 (0.39) | CCR1 | |
| SCHEMBL6272381 | 0.82 | CCR3 (0.34) | BCHECCR3DRD2CCR1DRD3 | |
| SCHEMBL6095898 | 0.81 | CCR1 (0.38) | CCR1OPRM1 | |
| SCHEMBL6095902 | 0.81 | CCR1 (0.38) | CCR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180929-A1 | Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents | KIM KYUNGJIN (US) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180929-A1 | Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents | PSMB1, UBQLN1, UBE2N | BCHE 1486/4885CCR3 3548/4885DRD2 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.